Cargando…
Implementation and use of whole exome sequencing for metastatic solid cancer
BACKGROUND: Genomically-guided clinical trials are performed across different tumor types sharing genetic mutations, but trial organization remains complex. Here we address the feasibility and utility of routine somatic and constitutional exome analysis in metastatic cancer patients. METHODS: Exoma...
Autores principales: | Réda, Manon, Richard, Corentin, Bertaut, Aurelie, Niogret, Julie, Collot, Thomas, Fumet, Jean David, Blanc, Julie, Truntzer, Caroline, Desmoulins, Isabelle, Ladoire, Sylvain, Hennequin, Audrey, Favier, Laure, Bengrine, Leila, Vincent, Julie, Hervieu, Alice, Dusserre, Jean-Florian Guion, Lepage, Come, Foucher, Pascal, Borg, Christophe, Albuisson, Juliette, Arnould, Laurent, Nambot, Sophie, Faivre, Laurence, Boidot, Romain, Ghiringhelli, Francois |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000332/ https://www.ncbi.nlm.nih.gov/pubmed/31923800 http://dx.doi.org/10.1016/j.ebiom.2019.102624 |
Ejemplares similares
-
Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
por: Guion-Dusserre, Jean-Florian, et al.
Publicado: (2016) -
Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series
por: Niogret, Julie, et al.
Publicado: (2022) -
Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
por: Bellio, Hélène, et al.
Publicado: (2021) -
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
por: Fumet, Jean-David, et al.
Publicado: (2018) -
Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
por: Galland, Loïck, et al.
Publicado: (2023)